ZHONGSHENGYAOYE(SZ:002317)2025-05-06 10:02Financial Performance - In 2024, the company reported a revenue of CNY 246,741.84 million, with a net loss attributable to shareholders of CNY 29,915.71 million, and a net loss of CNY 26,031.27 million after excluding non-recurring gains [2][4] - The decline in performance was attributed to the impact of centralized procurement pricing on the company's core product, the Compound Thrombus-Resolving Series [2] - Non-recurring gains decreased the net profit attributable to shareholders by CNY 3,884.44 million due to litigation-related provisions [2] Asset Impairment - The total asset impairment loss for 2024 was CNY 54,668.07 million, reducing the net profit attributable to shareholders by CNY 48,409.79 million [5][7] - Major impairment factors included inventory write-downs of CNY 5,472.75 million and goodwill impairment of CNY 20,167.71 million related to subsidiaries [5][7] - The company also recognized an impairment loss of CNY 7,916.66 million on intangible assets [5][7] Q1 2025 Performance - In Q1 2025, the company achieved a revenue of CNY 63,426.14 million, a year-on-year decrease of 1.07% [8] - The net profit attributable to shareholders was CNY 8,261.18 million, a year-on-year increase of 61.06% [8] - The net profit after excluding non-recurring gains was CNY 7,843.48 million, reflecting an increase of 8.60% year-on-year [8] R&D Pipeline - The company has established a multi-mode R&D ecosystem focusing on metabolic and respiratory diseases [9] - The innovative drug ZSP1601 for treating metabolic dysfunction-related fatty liver disease has completed Phase Ib/IIa clinical trials, showing significant reductions in liver inflammation markers [9][14] - The oral antiviral drug, Lai Rui Te Wei (乐睿灵®), has been approved for conditional marketing and included in the national medical insurance directory [10] New Drug Developments - The influenza drug Angrawei (安睿威®) has shown positive results in Phase III clinical trials and is under review for market approval [20] - The GLP-1 receptor agonist RAY1225 has completed Phase II trials, demonstrating significant weight loss and glycemic control in participants [15][18] - RAY1225 is expected to be a bi-weekly administered treatment for type 2 diabetes and obesity, with ongoing Phase III trials [15][18]